1. Scrip

Spain Biotech Boost As Minoryx Raises €21m

 
• By Kevin Grogan

Spain's biotech start-ups are building an impressive pipeline of drugs but have found financing a challenge, so news of fresh funds for rare diseases group Minoryx has been cheered by the sector.

Spanish flag
Minoryx flies flag for Spanish biotech in 2018 • Source: Shutterstock

As the luminaries of the country's biotech sector gathered in Seville for BioSpain to discuss how to raise its profile – and funds – news of a fresh injection of cash for Barcelona-based orphan disease specialist Minoryx Therapeutics SL went down very well with attendees.

Minoryx announced Sept. 26 the completion of a series B funding round of €21.3m, which CEO Marc Martinell said will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?